| Product Name | IFNa ELISA kit (Human) |
|---|---|
| Description | This assay has high sensitivity and excellent specificity for detection of Interferon Alpha (IFNa). No significant cross-reactivity or interference between Interferon Alpha (IFNa) and analogues was observed. |
| Synonyms | IFNA1; IFL; LeIF D; IFN; IFN-Alpha; IFNA13; IFN-A; IFNAP22; IFN-Alpha 1b; Interferon Alpha 1b; Interferon, Leukocytic; IFN, Leukocyte; Interferon alpha-D |
| Method | Sandwich |
| Detection Range | 7.8-500pg/mL |
| Sensitivity | 3.0pg/mL |
| Target | IFNa |
| Specificity | This assay has high sensitivity and excellent specificity for detection of Interferon Alpha (IFNa). No significant cross-reactivity or interference between Interferon Alpha (IFNa) and analogues was observed. |
| Reactivity | Human |
| Sample Types | Serum, Plasma, Tissue Homogenates, Cell Lysates, Cell Culture Supernates And Other Biological Fluids |
| Reconstitution | 1.Prepare all reagents, samples and standards; 2.Add 100uL standard or sample to each well.Incubate 2 hours at 37℃; 3.Aspirate and add 100uL prepared Detection Reagent A.Incubate 1 hour at 37℃; 4.Aspirate and wash 3 times; 5.Add 100uL prepared Detection Reagent B.Incubate 30 minutes at 37℃; 6.Aspirate and wash 5 times; 7.Add 90uL Substrate Solution.Incubate 10-20 minutes at 37℃; 8.Add 50uL Stop Solution.Read at 450nm immediately. |
| Uniprot | P01562 |
| Storage | 4°C for 1 month/ -20°C for long-term(within shelf life) |
| Notes | Colormetric |
| References | The cathelicidins LL-37 and rCRAMP are associated with pathogenic events of arthritis in humans and rats;Experimental rat model for alcohol-induced osteonecrosis of the femoral head;Andrographolide exerts anti-hepatitis C virus activity by up-regulating haeme oxygenase-1 via the p38 MAPK/Nrf2 pathway in human hepatoma cells;siRNA Targeting the 2A pro Genomic Region Prevents Enterovirus 71 Replication In Vitro;Sulforaphane Suppresses Hepatitis C Virus Replication by Up-ReCavia (Guinea pig )lating Heme Oxygenase-1 Expressionthrough PI3K/Nrf2 Pathway.;Host miR-146a promotes replication of human cytomegalovirus by suppressing type I IFN response in MRC-5 cells;MicroRNA-548j inhibits type I interferon production by targeting ZBTB11 in patients with chronic hepatitis B;Fucoidan from Fucus vesiculosus suppresses hepatitis B virus replication by enhancing extracellular signal-regulated Kinase activation.;Toll-like receptor 9 ligands increase type I interferon induced B-cell activating factor expression in chronic rhinosinusitis with nasal polyposis;Role of Toll‐like receptor 9 signaling on activation of nasal polyp–derived fibroblasts and its association with nasal polypogenesis;Collagen triple helix repeat containing-1: a novel biomarker associated with disease activity in Systemic lupus erythematosus;Scavenger receptor A impairs interferon response to HBV infection by limiting TRAF 3 ubiquitination through recruiting OTUB 1;Influenza virus neuraminidase regulates host CD8+ T-cell response in mice;IFN©\¦Á and TNF©\¦Á serum levels and their association with disease severity in Egyptian children and adults with alopecia areata;Orexin A Suppresses the Expression of Exosomal PD-L1 in Colon Cancer and Promotes T Cell Activity by Inhibiting JAK2/STAT3 Signaling Pathway;Clinical findings of Talaromyces marneffei infection among patients with anti-interferon-¦Ã immunodeficiency: a prospective cohort study;The anti-inflammatory activity of specific-sized hyaluronic acid oligosaccharides; |
| Supplier | Cloud Clone |
All Research Products are sold for laboratory RESEARCH USE ONLY and ARE NOT TO BE USED FOR HUMAN OR ANIMAL THERAPEUTIC OR DIAGNOSTIC APPLICATIONS. The information presented is believed to be accurate; however, said information and products are offered without warranty or guarantee since the ultimate conditions of use and the variability of the materials treated are beyond our control. Nothing disclosed herein is to be construed as a recommendation to use our products in violation of any patents. ARP American Research Products, Inc. does not submit its products for regulatory review by any government body or other organization, and we do not validate them for clinical, therapeutic or diagnostic use, or for safety and effectiveness. You are solely responsible for making sure that the way you use the products complies with applicable laws, regulations and governmental policies and for obtaining all necessary approvals, intellectual property rights, licenses and permissions that you may need related to your use. Under no circumstances shall ARP American Research Products, Inc. be liable for damages, whether consequential, compensatory, incidental or special, strict liability or negligence, breach of warranty or any other theory arising out of the use of the products available from ARP American Research Products, Inc. Nothing contained herein warrants that the use of the products will not infringe on the claims of any patents covering the product itself or the use thereof in combination with other products or in the operation of any process. ARP American Research Products, Inc. disclaims any and all representations or warranties of any kind whatsoever, express or implied, including without limitation any implied warranties of merchantability or fitness for a particular purpose, of non-infringement, or regarding results obtained through the use of any product, whether arising from a statute or otherwise in law or from a course of performance, dealing or usage of trade.